{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Progression-free survival (PFS) events include disease progression or death due to any cause.\n\nDisease progression was determined by the Investigator according to IMWG criteria.","groups":[{"description":"Participants with 1 prior line of therapy for multiple myeloma.","id":"OG000","title":"1 Prior Line of Therapy"},{"description":"Participants with ≥ 2 prior lines of therapy for multiple myeloma.","id":"OG001","title":"2+ Prior Lines of Therapy"}],"paramType":"NUMBER","populationDescription":"All enrolled and treated participants","reportingStatus":"POSTED","timeFrame":"Disease assessments were performed every 28 days up to 12 months from enrollment.","title":"Percentage of Participants With PFS Events by Prior Lines of Therapy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}